Кардиомиопатия - это термин, обозначающий заболевания сердечной мышцы. Их также иногда называют просто увеличенным сердцем. У людей с этими заболеваниями очень большое, толстое или твердое сердце. Их сердца не могут перекачивать достаточно крови. Если не лечить, кардиомиопатия ухудшится. Они могут привести к сердечной недостаточности и нарушению сердечного ритма. Кардиомиопатия иногда может быть наследственной, но также может быть вызвана высоким кровяным давлением, диабетом, ожирением, нарушениями обмена веществ или инфекциями. В статье мы подумаем об актуальности этого заболевания и новых методах его лечения.
Кардиомиопатия - это термин, обозначающий заболевания сердечной мышцы. Их также иногда называют просто увеличенным сердцем. У людей с этими заболеваниями очень большое, толстое или твердое сердце. Их сердца не могут перекачивать достаточно крови. Если не лечить, кардиомиопатия ухудшится. Они могут привести к сердечной недостаточности и нарушению сердечного ритма. Кардиомиопатия иногда может быть наследственной, но также может быть вызвана высоким кровяным давлением, диабетом, ожирением, нарушениями обмена веществ или инфекциями. В статье мы подумаем об актуальности этого заболевания и новых методах его лечения.
Kardiomiopatiya bu yurak muskullarining kasalliklari uchun atama hisoblanadi. Ular ba'zan oddiygina kengaygan yurak deb ham ataladi. Bunday kasalliklarga chalingan odamlarning yuraklari juda katta, qalin yoki qattiq holatda bo’ladi. Ularning yuraklari qonni kerakli darajada haydab bera olmaydi. Davolash muolajalari olib borilmasa, kardiyomiyopatiya yomonlashadi. Ular yurak yetishmovchiligiga va yurak ritmining buzilishiga olib kelishi mumkin. Kardiyomiyopatiya ba'zan irsiy paydo bo'lishi mumkin, ammo u yuqori qon bosimi, diabet, semizlik, metabolic kasalliklar yoki infektsiyalardan ham kelib chiqishi mumkin. Maqolada ushbu kasallikning dolzarbligi va uni davolashning yangi metodlari haqida fikr yuritamiz
This is the term for diseases of the heart muscle. They’re sometimes simply called enlarged heart. People with these conditions have hearts that are unusually big, thick, or stiff. Their hearts can’t pump blood as well as they should. Without treatment, cardiomyopathy get worse. They can lead to heart failure and abnormal heart rhythms.Cardiomyopathy may sometimes run in families, but it can also be caused by high blood pressure, diabetes, obesity, metabolic diseases, or infections.In the article we will think about the relevance of this disease and new methods of its treatment.
| № | Имя автора | Должность | Наименование организации |
|---|---|---|---|
| 1 | Nosirov M.. | . | Андижанский Государственный медицинский институт |
| № | Название ссылки |
|---|---|
| 1 | 1. Ethan J. Rowin, Barry J. Maron, Richard T. Carrick, Parth P. Patel, Ben Koethe, Sophie Wells, and Martin S. Maron. J Am CollCardiol. 2020 Jun, 75 (24) 3033–3043 |
| 2 | 2. Spirito, P., Seidman, C. E., McKenna, W. J., &Maron, B. J. (1997). The Management of Hypertrophic Cardiomyopathy. New |
| 3 | 3. Harjola VP, Lassus J, Sionis A, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail 2015; 17: 501–509. |
| 4 | 4. Schmidt M, Burrell A, Roberts L, et al. Predicting survival after ECMO for refractory cardiogenic shock: The Survival After Veno-arterial-ECMO (SAVE)-score. Eur Heart J 2015; 36: 2246–2256. |
| 5 | 5. Sieweke JT, Berliner D, Tongers J, et al. Mortality in patients with cardiogenic shock treated with the Impella CP microaxial pump for isolated left ventricular failure. Eur Heart J Acute Cardiovasc Care 2018. Epub ahead of print 9 February 2018. DOI: 10.1177/2048872618757393. |
| 6 | 6. Burzotta F, Trani C, Doshi SN, et al. Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. Int J Cardiol 2015; 201: 684– 691. |
| 7 | 7. Remmelink M, Sjauw KD, Henriques JP, et al. Effects of left ventricular unloading by Impella recover LP2.5 on coronary hemodynamics. Catheter CardiovascInterv 2007; 70: 532– 537. |
| 8 | 8. Sheu JJ, Tsai TH, Lee FY, et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med 2010; 38: 1810–1817. |
| 9 | 9. Sieweke, J.-T., Pfeffer, T. J., Berliner, D., König, T., Hallbaum, M., Napp, L. C., …Bauersachs, J. (2018). Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. European Heart Journal: Acute Cardiovascular Care, 204887261877787. doi:10.1177/2048872618777876. |
| 10 | 10. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 1995;92:785-9 |
| 11 | 11. Shapiro LM, Zezulka A. Hypertrophic cardiomyopathy: a common disease with a good prognosis: five year experience of a district general hospital. Br Heart J 1983;50:530-3. |
| 12 | prognosis: five year experience of a district general hospital. Br Heart J 1983;50:530-3. 12. Kofflard MJ, Waldstein DJ, Vos J, ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol 1993;72:939-43. |
| 13 | 13. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993;72:970-2 |
| 14 | 14. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994;90:2743-7. |
| 15 | 15. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995;26:1529-36. |
| 16 | 16. Cannan CR, Reeder GS, Bailey KR, Melton LJ III, Gersh BJ. Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. Circulation 1995;92:2488-95 |
| 17 | 17. Maron BJ, Henry WL, Clark CE, Redwood DR, Roberts WC, Epstein SE. Asymmetric septal hypertrophy in childhood. Circulation 1976;53:9 |
| 18 | 18. Fiddler GI, Tajik AJ, Weidman WH, McGoon DC, Ritter DG, Giuliani ER. Idiopathic hyp |
| 19 | 19. McKenna WJ, Deanfield J, Faruqui A, England D, Oakley CM, Goodwin JF. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47: 532-8 |
| 20 | 20. Seidman CE, Seidman JG. Gene mutations that cause familial hypertrophic - cardiomyopathy. In: Haber E, ed. Molecular cardiovascular medicine. New York: Scientific American, 1995:193-209. |
| 21 | 21. Thierfelder L, Watkins H, MacRae C, et al. a-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994;77:701-12 |
| 22 | 22. Watkins H, Anan R, Coviello DA, Spirito P, Seidman JG, Seidman CE. A de novo mutation in a-tropomyosin that causes hypertrophic cardiomyopathy. Circulation 1995;91:2302-5. |
| 23 | 23. Watkins H, Conner D, Thierfelder L, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995;11:434-7 |
| 24 | 24. Bonne G, Carrier L, Bercovici J, et al. Cardiac myosin binding proteinC gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 1995;11:438-40 |
| 25 | 25. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a RE-HEALTH JOURNAL №3 (11)-2021 RHJ №3-2021 28 report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;58:e212–e260. |
| 26 | 26. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–2779. |
| 27 | 27. Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, Felix SB, Arbustini E, Caforio ALP, Farmakis D, Filippatos GS, Gialafos E, Kanjuh V, Krljanac G, Limongelli G, Linhart A, Lyon AR, Maksimovic R, Milicic D, Milinkovic I, Noutsias M, Oto A, Oto O, Pavlovic SU, Piepoli MF, Ristic AD, Rosano GM, Seggewiss H, Asanin M, Seferovic JP, Ruschitzka F, Celutkiene J, Jaarsma T, Mueller C, Moura B, Hill L, Volterrani M, Lopatin Y, Metra M, Backs J, Mullens W, Chioncel O, de Boer RA, Anker S, Rapezzi C, Coats AJ, Tschope C. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:553–576. |
| 28 | 28. Spoladore R, Maron MS, D’Amato R, Camici PG, Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J 2012;33:1724– 1733 |
| 29 | 29. Cherian G, Brockington IF, Shah PM, Oakley CM, Goodwin JF. Beta-adrenergic blockade in hypertrophic obstructive cardiomyopathy. Br Med J 1966;1:895–898 |
| 30 | 30. Tuohy, C. V., Kaul, S., Song, H. K., Nazer, B., & Heitner, S. B. (2020). Hypertrophic cardiomyopathy: the future of treatment. European Journal of Heart Failure. doi:10.1002/ejhf.1715. |
| 31 | 31. Ventricular Arrhythmias in Ischemic Cardiomyopathy — New Avenues for MechanismGuided Treatment by Matthew Amoni, Eef Dries, Sebastian Ingelaere, Dylan Vermoortele, H. Llewelyn Roderick, Piet Claus, Rik Willems, and Karin R. Sipido. doi.org/10.3390/cells10102629. |
| 32 | 32. Zampieri, M., Berteotti, M., Ferrantini, C., Tassetti, L., Gabriele, M., Tomberli, B., … Olivotto, I. (2021). Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. Current Heart Failure Reports, 18(4), 169–179. doi:10.1007/s11897-021- 00523-0. |